Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review

March 2021 | 54 pages | ID: S02A37BDA45EN
GlobalData

Abstracts

Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy against partial-onset for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s diseases and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products SPN-830, SPN-812, SPN-817 and SPN-820. The company's technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc Key Recent Developments

Feb 25,2021: Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 23,2021: Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
Nov 03,2020: Supernus announces third quarter 2020 financial results
Oct 28,2020: Supernus to Host Third Quarter 2020 Financial Results Conference Call
Oct 05,2020: Supernus Pharmaceuticals appoints James Kelly as Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Supernus Pharmaceuticals Inc - Key Facts
Supernus Pharmaceuticals Inc - Key Employees
Supernus Pharmaceuticals Inc - Key Employee Biographies
Supernus Pharmaceuticals Inc - Major Products and Services
Supernus Pharmaceuticals Inc - History
Supernus Pharmaceuticals Inc - Company Statement
Supernus Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Supernus Pharmaceuticals Inc - Business Description
Business Segment: Licensing revenue
Performance
Business Segment: Net Product Sales
Performance
Business Segment: Royalty Revenue
Performance
R&D Overview
Supernus Pharmaceuticals Inc - Corporate Strategy
Supernus Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Supernus Pharmaceuticals Inc - Strengths
Supernus Pharmaceuticals Inc - Weaknesses
Supernus Pharmaceuticals Inc - Opportunities
Supernus Pharmaceuticals Inc - Threats
Supernus Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Supernus Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2021: Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
Feb 23, 2021: Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
Nov 03, 2020: Supernus announces third quarter 2020 financial results
Oct 28, 2020: Supernus to Host Third Quarter 2020 Financial Results Conference Call
Oct 05, 2020: Supernus Pharmaceuticals appoints James Kelly as Chief Financial Officer
Aug 18, 2020: Supernus announces second quarter 2020 financial results
Aug 11, 2020: Supernus announces preliminary second quarter 2020 revenue
May 05, 2020: Supernus announces first quarter 2020 financial results
Mar 30, 2020: Supernus provides business update
Feb 25, 2020: Supernus announces fourth quarter and full year 2019 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Supernus Pharmaceuticals Inc, Key Facts
Supernus Pharmaceuticals Inc, Key Employees
Supernus Pharmaceuticals Inc, Key Employee Biographies
Supernus Pharmaceuticals Inc, Major Products and Services
Supernus Pharmaceuticals Inc, History
Supernus Pharmaceuticals Inc, Subsidiaries
Supernus Pharmaceuticals Inc, Key Competitors
Supernus Pharmaceuticals Inc, Ratios based on current share price
Supernus Pharmaceuticals Inc, Annual Ratios
Supernus Pharmaceuticals Inc, Annual Ratios (Cont...1)
Supernus Pharmaceuticals Inc, Annual Ratios (Cont...2)
Supernus Pharmaceuticals Inc, Interim Ratios
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Supernus Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Supernus Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Supernus Pharmaceuticals Inc, Ratio Charts
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021